Flavin-containing monooxygenase 1-catalysed N,N-dimethylamphetamine N-oxidation DMA

Xenobiotica

Volumn 39, Issue 9, 2009, Pages 680-686

  Lee, S K ^a   Kang, M J ^a   Jin, C ^a   In, M K ^b   Kim, D H ^c   Yoo, H H ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Supreme Prosecutors' Office   (South Korea)

^c Yuyu Pharma Inc   (South Korea)

Author keywords

Flavin containing monooxygenase; N,N dimethylamphetamine (DMA); N,N dimethylamphetamine N oxide (DMANO); N oxidation

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIMETAMFETAMINE; DIMETHYLANILINE MONOOXYGENASE; IMIPRAMINE; PROTEIN; ADRENERGIC RECEPTOR AFFECTING AGENT; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); DRUG DERIVATIVE; METHAMPHETAMINE; OXYGENASE;

ARTICLE; CATALYST; CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MICHAELIS MENTEN KINETICS; OXIDATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; KINETICS; MASS SPECTROMETRY; METABOLISM; OXIDATION REDUCTION REACTION;

ADRENERGIC UPTAKE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMIPRAMINE; KINETICS; MASS SPECTROMETRY; METHAMPHETAMINE; OXIDATION-REDUCTION; OXYGENASES;

EID: 70350510900     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902998699     Document Type: Article

References (24)

1. Bach MV, Coutts RT, Baker GB. (1999). Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 29:719-732
2. Bach MV, Coutts RT, Baker GB. (2000). Metabolism of N,N-dialkylated amphetamines including deprenyl, by CYP2D6 expressed in a human cell line. Xenobiotica 30:297-306.
3. Beckett AH, Al-Sarraj SM. (1972). The metabolism of (+)-and (-)-amphetamines and (+)- and (-)-dimethylamphetamine in rabbits in vivo. Biochem J 130:14.
4. Cashman JR. (2000). Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab 1:181-191
5. Cashman JR, Xiong YN, Xu L, Janowsky A. (1999). N-oxygenation of amphetamine and methamphetamine by the human flavincontaining monooxygenase (Form 3): role in bioactivation and detoxication. J Pharmacol Exp Ther 288:1251-1260
6. Cashman JR, Zhang J. (2006). Human flavin-containing monooxygenase. Ann Rev Pharmacol Toxicol 46:65-100.
7. Cheng WC, Mok VK, Chan KK, Li AF. (2007). A rapid and convenient LC/MS method for routine identification of methamphetamine/ dimethylamphetamine and their metabolites in urine. Forensic Sci Int 166:1-7.
8. Clement B, Demesmaeker M, Linn S. (1996). Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz. Chem Res Toxicol 9:682-688
9. Dixit A, Roche TE. (1984). Spectrophotometric assay of the flavincontaining monooxygenase and changes in its activity in female mouse liver with nutritional and diurnal conditions. Archiv Biochem Biophys 233:50-63.
10. Eswaramoorthy S, Bonanno JB, Burley SK, Swaminathan S. (2006). Mechanism of action of a flavin-containing monooxygenase. Proc Natl Acad Sci USA 103:9832-9837
11. Hutchaleelaha A, Mayersohn M. (1997). p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. Biopharmaceut Drug Disposit 18:423-432
12. Inoue T, Suzuki S. (1987). The metabolism of dimethylamphetamine in rat and human. Xenobiotica 17:965-971
13. Jenner P. (1971). The role of nitrogen oxidation in the excretion of drugs and foreign compounds. Xenobiotica 1:399-418.
14. Katz JL, Ricaurte GA, Witkin JM. (1992). Reinforcing effects of enantiomers of N,N-dimethylamphetamine in squirrel monkeys. Psychopharmacology 107:315-318
15. Kim YM, Ziegler DM. (2000). Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Disposit 28:1003-1006
16. Kreth K, Kovar K, Schwab M, Zanger UM, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK. (2000). Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem Pharmacol 59:1563-1571
17. Lang DH, Rettie AE. (2000). In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol 50:311-314
18. Lin LY, Di Stefano EW, Schmitz DA. (1997). Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Disposit 25:1059-1064
19. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. (2000). Toxicokinetics and analytical toxicology of amphetamine- derived designer drugs ('Ecstasy'). Toxicol Lett 112-13:133-142
20. Moody DE, Ruangyuttikarn W, Law MY. (1990). Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Analyt Toxicol 14:311-317
21. Moroni P, Longin-Sauvageon C, Benoit E. (1995). The flavin- containing monooxygenase in rat liver: evidence for the expression of a second form different from FMO1. Biochem Biophys Res Comm 212:820-826
22. Nace CG, Genter MB, Sayre LM, Crofton KM. (1997). Effect of methimazole, an FMO substrate and competitive inhibitor, on the neurotoxicity of 3,39-iminodipropionitrile in male rats. Fund Appl Toxicol 37:131-140
23. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, Philpot RM. (1995). Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit orthologs. Archiv Biochem Biophys 327:275-284
24. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. (1997). Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53:1605-1612